{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T00:44:37Z","timestamp":1784681077075,"version":"3.55.0"},"reference-count":32,"publisher":"e-Century Publishing Corporation","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Am J Cancer Res"],"DOI":"10.62347\/gjnn1023","type":"journal-article","created":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T07:04:45Z","timestamp":1756451085000},"page":"3417-3433","source":"Crossref","is-referenced-by-count":1,"title":["Outpatient axicabtagene ciloleucel for relapsed\/refractory large B-cell lymphoma: ZUMA-24 primary analysis"],"prefix":"10.62347","volume":"15","author":[{"given":"Lori A","family":"Leslie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"48694","published-online":{"date-parts":[[2025]]},"reference":[{"key":"ref0","unstructured":"YESCARTA® (axicabtagene ciloleucel) Summary of product characteristics. Amsterdam, the Netherlands: Kite Pharma EU B.V.; 2024."},{"key":"ref1","unstructured":"YESCARTA® (axicabtagene ciloleucel) Prescribing information. Kite Pharma, Inc; 2024."},{"key":"ref2","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1056\/NEJMoa2116133","article-title":"Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma","volume":"386","author":"FL","year":"2022","unstructured":"Locke FL, Miklos DB, Jacobson CA, Perales MA, Kersten MJ, Oluwole OO, Ghobadi A, Rapoport AP, McGuirk J, Pagel JM, Munoz J, Farooq U, van Meerten T, Reagan PM, Sureda A, Flinn IW, Vandenberghe P, Song KW, Dickinson M, Minnema MC, Riedell PA, Leslie LA, Chaganti S, Yang Y, Filosto S, Shah J, Schupp M, To C, Cheng P, Gordon LI and Westin JR; All ZUMA-7 Investigators and Contributing Kite Members. Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma. N Engl J Med 2022; 386: 640-654.","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","unstructured":"Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, Braunschweig I, Oluwole OO, Siddiqi T, Lin Y, Timmerman JM, Stiff PJ, Friedberg JW, Flinn IW, Goy A, Hill BT, Smith MR, Deol A, Farooq U, McSweeney P, Munoz J, Avivi I, Castro JE, Westin JR, Chavez JC, Ghobadi A, Komanduri KV, Levy R, Jacobsen ED, Witzig TE, Reagan P, Bot A, Rossi J, Navale L, Jiang Y, Aycock J, Elias M, Chang D, Wiezorek J and Go WY. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med 2017; 377: 2531-2544.","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1056\/NEJMoa2301665","article-title":"Survival with axicabtagene ciloleucel in large B-cell lymphoma","volume":"389","author":"JR","year":"2023","unstructured":"Westin JR, Oluwole OO, Kersten MJ, Miklos DB, Perales MA, Ghobadi A, Rapoport AP, Sureda A, Jacobson CA, Farooq U, van Meerten T, Ulrickson M, Elsawy M, Leslie LA, Chaganti S, Dickinson M, Dorritie K, Reagan PM, McGuirk J, Song KW, Riedell PA, Minnema MC, Yang Y, Vardhanabhuti S, Filosto S, Cheng P, Shahani SA, Schupp M, To C and Locke FL; ZUMA-7 Investigators; Kite Members. Survival with axicabtagene ciloleucel in large B-cell lymphoma. N Engl J Med 2023; 389: 148-157.","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1038\/s41409-023-02169-z","article-title":"Long-term outcomes of patients with large B-cell lymphoma treated with axicabtagene ciloleucel and prophylactic corticosteroids","volume":"59","author":"OO","year":"2024","unstructured":"Oluwole OO, Forcade E, Muñoz J, de Guibert S, Vose JM, Bartlett NL, Lin Y, Deol A, McSweeney P, Goy AH, Kersten MJ, Jacobson CA, Farooq U, Minnema MC, Thieblemont C, Timmerman JM, Stiff P, Avivi I, Tzachanis D, Zheng Y, Vardhanabhuti S, Nater J, Shen RR, Miao H, Kim JJ and van Meerten T. Long-term outcomes of patients with large B-cell lymphoma treated with axicabtagene ciloleucel and prophylactic corticosteroids. Bone Marrow Transplant 2024; 59: 366-372.","journal-title":"Bone Marrow Transplant"},{"key":"ref6","unstructured":"Bansal R, Hsu H, Paludo J, Du B, Corraes ADMS, Johnston P, Khurana A, Wang Y, Fu C, Kim JJ, Song Q, Wu J, Sun F and Lin Y. Updated trends in real-world outpatient (OP) administration of axicabtagene ciloleucel (axi-cel) and brexucabtagene autoleucel (brexu-cel) in relapsed\/refractory (R\/R) non-Hodgkin lymphoma (NHL). European Hematology Association Annual Congress 2024; P1191."},{"key":"ref7","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","unstructured":"Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, Advani R, Ghielmini M, Salles GA, Zelenetz AD and Jaffe ES. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 2016; 127: 2375-2390.","journal-title":"Blood"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"BD","year":"2014","unstructured":"Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E and Lister TA; Alliance, Australasian Leukaemia and Lymphoma Group; Eastern Cooperative Oncology Group; European Mantle Cell Lymphoma Consortium; Italian Lymphoma Foundation; European Organisation for Research; Treatment of Cancer\/Dutch Hemato-Oncology Group; Grupo Español de Médula Ósea; German High-Grade Lymphoma Study Group; German Hodgkin’s Study Group; Japanese Lymphorra Study Group; Lymphoma Study Association; NCIC Clinical Trials Group; Nordic Lymphoma Study Group; Southwest Oncology Group; United Kingdom National Cancer Research Institute. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 2014; 32: 3059-3068.","journal-title":"J Clin Oncol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current concepts in the diagnosis and management of cytokine release syndrome","volume":"124","author":"Lee","year":"2014","unstructured":"Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA and Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood 2014; 124: 188-195.","journal-title":"Blood"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S1470-2045(14)71170-2","article-title":"Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study","volume":"16","author":"MS","year":"2015","unstructured":"Topp MS, Gökbuget N, Stein AS, Zugmaier G, O’Brien S, Bargou RC, Dombret H, Fielding AK, Heffner L, Larson RA, Neumann S, Foà R, Litzow M, Ribera JM, Rambaldi A, Schiller G, Brüggemann M, Horst HA, Holland C, Jia C, Maniar T, Huber B, Nagorsen D, Forman SJ and Kantarjian HM. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Oncol 2015; 16: 57-66.","journal-title":"Lancet Oncol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.ymthe.2016.10.020","article-title":"Phase 1 results of ZUMA-1: a multicenter study of KTE-C19 anti-CD19 CAR T cell therapy in refractory aggressive lymphoma","volume":"25","author":"Locke","year":"2017","unstructured":"Locke FL, Neelapu SS, Bartlett NL, Siddiqi T, Chavez JC, Hosing CM, Ghobadi A, Budde LE, Bot A, Rossi JM, Jiang Y, Xue AX, Elias M, Aycock J, Wiezorek J and Go WY. Phase 1 results of ZUMA-1: a multicenter study of KTE-C19 anti-CD19 CAR T cell therapy in refractory aggressive lymphoma. Mol Ther 2017; 25: 285-295.","journal-title":"Mol Ther"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"11","DOI":"10.46989\/001c.115793","article-title":"Outpatient CAR T-cell therapy as standard of care: current perspectives and considerations","volume":"6","author":"Gatwood","year":"2024","unstructured":"Gatwood K, Mahmoudjafari Z, Baer B, Pak S, Lee B, Kim H, Abernathy K, Dholaria B and Oluwole O. Outpatient CAR T-cell therapy as standard of care: current perspectives and considerations. Clin Hematol Int 2024; 6: 11-20.","journal-title":"Clin Hematol Int"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/j.jtct.2021.01.014","article-title":"Chimeric antigen receptor t cell therapy: a comprehensive review of clinical efficacy, toxicity, and best practices for outpatient administration","volume":"27","author":"Alexander","year":"2021","unstructured":"Alexander M, Culos K, Roddy J, Shaw JR, Bachmeier C, Shigle TL and Mahmoudjafari Z. Chimeric antigen receptor t cell therapy: a comprehensive review of clinical efficacy, toxicity, and best practices for outpatient administration. Transplant Cell Ther 2021; 27: 558-570.","journal-title":"Transplant Cell Ther"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"Oluwole OO, Wade SW, Smith NJ, Spousta T, Kim JJ, Zheng Y, Best T, Ray M and Leslie LA. Short-term costs associated with outpatient use of axicabtagene ciloleucel in second-line relapsed\/refractory large B-cell lymphoma based on zuma-24 clinical trial. Presented at the Tandem Meetings of the ASTCT and CIBMTR 2025; 563.","DOI":"10.1016\/j.jtct.2025.01.616"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1080\/13696998.2023.2290832","article-title":"An updated cost-effectiveness analysis of axicabtagene ciloleucel in second-line large B-cell lymphoma patients in the United States","volume":"27","author":"Oluwole","year":"2024","unstructured":"Oluwole OO, Patel AR, Vadgama S, Smith NJ, Blissett R, Feng C, Dickinson M, Johnston PB and Perales MA. An updated cost-effectiveness analysis of axicabtagene ciloleucel in second-line large B-cell lymphoma patients in the United States. J Med Econ 2024; 27: 77-83.","journal-title":"J Med Econ"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1080\/13696998.2018.1529674","article-title":"Cost-effectiveness of axicabtagene ciloleucel for adult patients with relapsed or refractory large B-cell lymphoma in the United States","volume":"21","author":"Roth","year":"2018","unstructured":"Roth JA, Sullivan SD, Lin VW, Bansal A, Purdum AG, Navale L, Cheng P and Ramsey SD. Cost-effectiveness of axicabtagene ciloleucel for adult patients with relapsed or refractory large B-cell lymphoma in the United States. J Med Econ 2018; 21: 1238-1245.","journal-title":"J Med Econ"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"5746","DOI":"10.3390\/cancers15245746","article-title":"The impact of outpatient versus inpatient administration of CAR-T therapies on clinical, economic, and humanistic outcomes in patients with hematological cancer: a systematic literature review","volume":"15","author":"Hansen","year":"2023","unstructured":"Hansen DK, Liu YH, Ranjan S, Bhandari H, Potluri R, McFarland L, De Braganca KC and Huo S. The impact of outpatient versus inpatient administration of CAR-T therapies on clinical, economic, and humanistic outcomes in patients with hematological cancer: a systematic literature review. Cancers (Basel) 2023; 15: 5746.","journal-title":"Cancers (Basel)"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"1412002","DOI":"10.3389\/fimmu.2024.1412002","article-title":"Outpatient administration of CAR T-cell therapy: a focused review with recommendations for implementation in community based centers","volume":"15","author":"Perez","year":"2024","unstructured":"Perez A, Al Sagheer T, Nahas GR and Linhares YPL. Outpatient administration of CAR T-cell therapy: a focused review with recommendations for implementation in community based centers. Front Immunol 2024; 15: 1412002.","journal-title":"Front Immunol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1111\/bjh.18339","article-title":"Feasibility of outpatient administration of axicabtagene ciloleucel and brexucabtagene autoleucel using telemedicine tools: the Vanderbilt experience","volume":"198","author":"Dholaria","year":"2022","unstructured":"Dholaria B, Mehraban N, Baer B, Long N, Jayani RV, Byrne MT, Kassim AA, Engelhardt BG, Savani BN and Oluwole OO. Feasibility of outpatient administration of axicabtagene ciloleucel and brexucabtagene autoleucel using telemedicine tools: the Vanderbilt experience. Br J Haematol 2022; 198: 1073-1075.","journal-title":"Br J Haematol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1038\/s41409-022-01664-z","article-title":"Safety and feasibility of outpatient chimeric antigen receptor (CAR) T-cell therapy: experience from a tertiary care center","volume":"57","author":"Borogovac","year":"2022","unstructured":"Borogovac A, Keruakous A, Bycko M, Holter Chakrabarty J, Ibrahimi S, Khawandanah M, Selby GB, Yuen C, Schmidt S, Autry MT, Al-Juhaishi T, Wieduwilt MJ and Asch AS. Safety and feasibility of outpatient chimeric antigen receptor (CAR) T-cell therapy: experience from a tertiary care center. Bone Marrow Transplant 2022; 57: 1025-1027.","journal-title":"Bone Marrow Transplant"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1111\/bjh.19090","article-title":"Outpatient CD19-directed CAR T-cell therapy is feasible in patients of all ages","volume":"203","author":"Ly","year":"2023","unstructured":"Ly A, Sanber K, Tsai HL, Ondo A, Mooney K, Shedeck A, Baker J, Imus PH, Wagner-Johnston N and Jain T. Outpatient CD19-directed CAR T-cell therapy is feasible in patients of all ages. Br J Haematol 2023; 203: 688-692.","journal-title":"Br J Haematol"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"Battiwalla M, Tees M, Flinn IW, Pantin J, Gregory T, Maris MB, Bhushan V, Vance E, Mathews J, Bachier C, haughnessy PJ, Ramakrishnan A, Malik S, Mori S, Gergis U, Gillups R, Blunk B, LeMaistre CF and Majhail NS. Outcomes for anti-CD19+ chimeric antigen receptor T (CAR-T) cell therapy for non hodgkin lymphoma (NHL) across a large community transplant and cellular therapy network. Transplantation and Cellular Therapy 2023; 29: S211.","DOI":"10.1016\/S2666-6367(23)00342-1"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"2248","DOI":"10.1182\/blood.2022015478","article-title":"Patient-reported outcomes in ZUMA-7, a phase 3 study of axicabtagene ciloleucel in second-line large B-cell lymphoma","volume":"140","author":"Elsawy","year":"2022","unstructured":"Elsawy M, Chavez JC, Avivi I, Larouche JF, Wannesson L, Cwynarski K, Osman K, Davison K, Rudzki JD, Dahiya S, Dorritie K, Jaglowski S, Radford J, Morschhauser F, Cunningham D, Martin Garcia-Sancho A, Tzachanis D, Ulrickson ML, Karmali R, Kekre N, Thieblemont C, Enblad G, Dreger P, Malladi R, Joshi N, Wang WJ, Solem CT, Snider JT, Cheng P, To C and Kersten MJ. Patient-reported outcomes in ZUMA-7, a phase 3 study of axicabtagene ciloleucel in second-line large B-cell lymphoma. Blood 2022; 140: 2248-2260.","journal-title":"Blood"},{"key":"ref24","unstructured":"Lin VW, Jiang Y, Chuang LH, Navale L, Cheng P and Purdum A. Health utilities for patients with relapsed or refractory large B cell lymphoma (R\/R-LBCL) Ad Hoc analysis from an axicabtagene ciloleucel (Axi-Cel) safety management study. Bone Marrow Transplant 2018."},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"Hoogland AI, Li X, Modi K, Welniak T, Rodriguez Y, Irizarry-Arroyo N, Oswald LB, Snider JT, Wade SW, Chavez J, Corallo S, Booth-Jones M, Jain MD, Locke FL and Jim HSL. Real-world patient-reported and neurocognitive outcomes in the year after axicabtagene ciloleucel. Transplant Cell Ther 2025; 31: 157.e1-157.e13.","DOI":"10.1016\/j.jtct.2024.12.020"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1182\/blood.2023020578","article-title":"Immune effector cell-associated hematotoxicity: EHA\/EBMT consensus grading and best practice recommendations","volume":"142","author":"Rejeski","year":"2023","unstructured":"Rejeski K, Subklewe M, Aljurf M, Bachy E, Balduzzi A, Barba P, Bruno B, Benjamin R, Carrabba MG, Chabannon C, Ciceri F, Corradini P, Delgado J, Di Blasi R, Greco R, Houot R, Iacoboni G, Jäger U, Kersten MJ, Mielke S, Nagler A, Onida F, Peric Z, Roddie C, Ruggeri A, Sánchez-Guijo F, Sánchez-Ortega I, Schneidawind D, Schubert ML, Snowden JA, Thieblemont C, Topp M, Zinzani PL, Gribben JG, Bonini C, Sureda A and Yakoub-Agha I. Immune effector cell-associated hematotoxicity: EHA\/EBMT consensus grading and best practice recommendations. Blood 2023; 142: 865-877.","journal-title":"Blood"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"879608","DOI":"10.3389\/fimmu.2022.879608","article-title":"Immune effector cell associated neurotoxicity syndrome in chimeric antigen receptor-T cell therapy","volume":"13","author":"Sterner","year":"2022","unstructured":"Sterner RC and Sterner RM. Immune effector cell associated neurotoxicity syndrome in chimeric antigen receptor-T cell therapy. Front Immunol 2022; 13: 879608.","journal-title":"Front Immunol"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1182\/bloodadvances.2019000952","article-title":"Comparing CAR T-cell toxicity grading systems: application of the ASTCT grading system and implications for management","volume":"4","author":"Pennisi","year":"2020","unstructured":"Pennisi M, Jain T, Santomasso BD, Mead E, Wudhikarn K, Silverberg ML, Batlevi Y, Shouval R, Devlin SM, Batlevi C, Brentjens RJ, Dahi PB, Diamonte C, Giralt S, Halton EF, Maloy M, Palomba ML, Sanchez-Escamilla M, Sauter CS, Scordo M, Shah G, Park JH and Perales MA. Comparing CAR T-cell toxicity grading systems: application of the ASTCT grading system and implications for management. Blood Adv 2020; 4: 676-686.","journal-title":"Blood Adv"},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"Beaupierre A, Kahle N, Lundberg R and Patterson A. Educating multidisciplinary care teams, patients, and caregivers on CAR T-cell therapy. J Adv Pract Oncol 2019; 10 Suppl 3: 29-40.","DOI":"10.6004\/jadpro.2019.10.4.12"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1200\/CCI.21.00023","article-title":"Next-generation implementation of chimeric antigen receptor T-cell therapy using digital health","volume":"5","author":"Banerjee","year":"2021","unstructured":"Banerjee R, Shah N and Dicker AP. Next-generation implementation of chimeric antigen receptor T-cell therapy using digital health. JCO Clin Cancer Inform 2021; 5: 668-678.","journal-title":"JCO Clin Cancer Inform"},{"key":"ref31","doi-asserted-by":"publisher","unstructured":"Cox T, Zahradka N, Billups RL, Blunk B, Campo R, Carelock T, Husband M, LeMaistre CF, Majhail N, Martin C, Meissner S, Pantin J, Perez M, Pugmire J, Ramkrishnan A, Shaughnessy P, Smith A, Tees MT, Wilkes M, Yates M and Battiwalla M. Standardization of outpatient care after CAR-T therapy across a large cell therapy network - through technology and decentralized virtual nurses: preliminary results. The American Society of Hematology Annual Meeting 2023.","DOI":"10.1182\/blood-2023-187253"}],"container-title":["American Journal of Cancer Research"],"original-title":[],"link":[{"URL":"https:\/\/e-century.us\/files\/ajcr\/15\/8\/ajcr0166149.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T01:58:30Z","timestamp":1766023110000},"score":1,"resource":{"primary":{"URL":"https:\/\/e-century.us\/files\/ajcr\/15\/8\/ajcr0166149.pdf"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":32,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.62347\/gjnn1023","relation":{},"ISSN":["2156-6976"],"issn-type":[{"value":"2156-6976","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]}}}